Safety, Antiviral Activity and PK of MRD of BI 201335 in Chronic Hepatitis C Patients Both Treatment Naive and -Experienced
Status:
Completed
Trial end date:
2011-01-25
Target enrollment:
Participant gender:
Summary
This study will investigate safety, antiviral activity, and pharmacokinetics of BI 201335 NA
in HCV genotype 1 infected patients treated for 14 days monotherapy followed by BI 201335 NA
combination therapy with PegIFN/RBV for an additional 14 days for treatment-naïve patients;
or for 28 days as BI 201335 NA combination therapy with PegIFN/RBV for treatment-experienced
patients.
A secondary objective is to investigate antiviral activity, potential drug-drug interactions
and safety of combination therapy of BI 201335 NA and PegIFN/RBV up to 28 days for
treatment-naïve patients.